Cardiovascular disease is the leading cause of mortality in patients with chronic kidney disease (CKD) and dyslipidaemia is an important contributor. The use of statins in this subgroup of patients appears to be beneficial in lowering the cardiovascular (CV) risk from the body of evidence available, although there are some important considerations that need to be taken into account. These include the dose and choice of statin, depending on the stage of the CKD and risk profile of the patient. This review looks at some of the important studies that support the clinical use of statins in patients with CKD and summarises some of the key points that the practising clinician should consider.